Anzeige
Mehr »
Donnerstag, 14.05.2026 - Börsentäglich über 12.000 News
Vom Explorer zur Gelddruckmaschine? Dieser Goldwert zündet gerade die nächste Stufe
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0NEYG | ISIN: US30211M1036 | Ticker-Symbol: N/A
1-Jahres-Chart
EXOUSIA ADVANCED MATERIALS INC Chart 1 Jahr
5-Tage-Chart
EXOUSIA ADVANCED MATERIALS INC 5-Tage-Chart

Aktuelle News zur EXOUSIA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoExousia Pro, Inc.: NexTel Medical Corp Enters Final Stage for Commercial Launch; Sets Sights on Revenue Generation and OTCQB Uplist170ORLANDO, Fla., May 11, 2026 (GLOBE NEWSWIRE) -- NexTel Medical Corp (f/k/a Exousia Pro, Inc.) (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery...
► Artikel lesen
14.04.Exousia Bio, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB-
07.04.Exousia Pro, Inc.: NexTel Medical Corp Announces Pivotal Milestone in Commercial Launch of Patent-Protected NANOG DNA Cancer Screening Test1
17.03.Exousia Bio, Inc. - 10-Q, Quarterly Report1
16.03.Exousia Pro, Inc. Announces Favorable Litigation Settlement, Highlighting Significant Debt Elimination and Share Cancellation to Enhance Shareholder Value487ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Exousia Pro, Inc. (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, today announced...
► Artikel lesen
05.03.Exousia Pro, Inc. Announces Strategic Elimination of Future Dilutive Issuance of 47 Million Shares, Progresses Toward Definitive Agreements for Telehealth Acquisitions122ORLANDO, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- Exousia Pro, Inc. (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, is pleased to announce...
► Artikel lesen
EXOUSIA Aktie jetzt für 0€ handeln
10.02.Exousia Pro, Inc. Accelerates Strategic Expansion with Third Telehealth Acquisition; Strengthens Pathway to Low-Cost Customer Acquisition1
11.12.25Exousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform to Accelerate Nutraceutical Commercialization456ORLANDO, FL / ACCESS Newswire / December 11, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on proprietary exosome-based delivery systems, is excited to announce...
► Artikel lesen
05.12.25Exousia Pro, Inc. Revolutionizes Nutraceuticals With Launch Of Maxasome: The First All-Natural, Biologically Active Exosomal Supplement418ORLANDO, FLORIDA / ACCESS Newswire / December 5, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company leveraging proprietary exosome-based delivery systems, today announced...
► Artikel lesen
04.12.25Renowned Immunologist and Urological Surgeon Dr. Marvin Hausman Featured in New Exousia Bio, Inc. Interview1
02.12.25Exousia Pro, Inc. Completes Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms481ORLANDO, FLORIDA / ACCESS Newswire / December 2, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on advanced exosome-based delivery systems, today announced the...
► Artikel lesen
02.12.25Exousia Bio, Inc.: LAMY Completes Strategic Acquisition of Cancer Therapy Innovator Exousia AI, Inc.352EXOUSIA AI SECURES HIGH-VALUE ORPHAN DRUG DESIGNATION ORLANDO, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) (the "Company" or "Exo Bio"), operating as...
► Artikel lesen
17.11.25Exousia Pro, Inc.: Exousia Pro Initiates Strategic Realignment, Acquires Controlling Stake in SEC-Reporter Lamy in All-stock Exchange Transaction for Exousia AI, to Advance Growth and Enhance Shareholder Value496ORLANDO, FLORIDA / ACCESS Newswire / November 17, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on advanced exosome-based delivery systems, today announced it...
► Artikel lesen
04.11.25Exousia Pro, Inc.: Exousia Pro Announces Breakthrough In Exosome-Based Delivery648Successful loading of CBD material accelerates the path to revenue. ORLANDO, FL / ACCESS Newswire / November 4, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company focused...
► Artikel lesen
28.10.25Exousia Pro, Inc.: Exousia Pro is Excited to Announce that it has Received Orphan Drug Designation from the FDA467Exousia Pro is in a unique position, as only 11% of ODAs are awarded at the preclinical stage. ORLANDO, FLORIDA / ACCESS Newswire / October 28, 2025 / Exousia Pro, Inc. (formerly Marijuana, Inc.) (OTCPINK:MAJI)...
► Artikel lesen
29.09.25Exousia Pro, Inc.: Exousia Pro Announces Groundbreaking Study to Revolutionize the Global Edibles Market with CBD-Loaded Exosomes508ORLANDO, FLORIDA / ACCESS Newswire / September 29, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company focused on advanced exosome-based therapies, today announced its plan...
► Artikel lesen
26.09.25Exousia Pro, Inc.: Exousia Pro Reports Positive Outcome in Legal Proceeding485Focused on Protecting Shareholder Value and Advancing Core Business ORLANDO, FLORIDA / ACCESS Newswire / September 26, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company...
► Artikel lesen
10.09.25Exousia Pro, Inc.: Exousia Pro Files Provisional Patent for Novel Extracellular Vesicle Loading Method, Tapping into Multi-Billion Dollar Markets393ORLANDO, FL / ACCESS Newswire / September 10, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company and innovator in exosome-based therapies, today announced a key strategic...
► Artikel lesen
08.09.25Exousia Pro, Inc.: Exousia Pro Announces Strategic Acquisition to Launch a New Telehealth Division541Exousia Health is expected to have an initial patient base of 1,000 active clients, projected to generate approximately $50,000 in monthly revenue. ORLANDO, FL / ACCESS Newswire / September 8, 2025...
► Artikel lesen
03.09.25Exousia Pro, Inc.: Exousia Pro Creates New Subdivisions570Exousia Pro aims to develop three new subdivisions and launch new products during the 4th quarter.The market for our new products is currently valued at $8.7 billion, projected to grow to $18.5 billion...
► Artikel lesen
Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1